Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $3.12, $0.62 better than the analyst estimate of $2.50. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $984.86 million.

GUIDANCE:

Charles River Laboratories sees FY2025 EPS of $9.90-$10.10, versus the consensus of $9.65.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.